Parkinson's Disease Trial, Recruiting NCT06920134 Sponsor: Ecole Polytechnique Fédérale de Lausanne Condition: Parkinson's Disease
Back to Parkinsons Disease

Parkinson's Disease Trial, Recruiting

NCT06920134
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are over 18 years old
  • People who have been diagnosed with a typical or atypical form of Parkinson's disease, which may include conditions such as Multiple System Atrophy, Pure Autonomic Failure, or Progressive Supranuclear Palsy
  • People who have a confirmed drop in blood pressure when standing up, shown through a specific standing test
  • People whose blood pressure drop when standing causes significant difficulties with everyday activities, as assessed by the study doctors
  • People who are willing and able to sign a consent form before any study procedures begin
  • People whose overall medical, physical, and psychological health is considered stable enough by the study team
  • People who are able to communicate in French or English with the study team
  • People who are willing to follow all study requirements and attend all scheduled visits

Who may not be able to join:

  • People who have health conditions that would make the implantation surgery more risky or dangerous
  • People who are unable to temporarily stop taking blood-thinning or anti-clotting medications around the time of surgery
  • People who have had a heart attack or stroke within the past 6 months
  • People who have an unstable or significant health condition that could interfere with the study or make the results harder to interpret, as decided by the study doctor
  • People who have a history of, or are currently experiencing, a major psychiatric condition or significant problems with memory and thinking, as assessed by the study team together with the treating doctor and neurologist
  • People who have major changes to their Parkinson's disease treatment planned before the end of the main study phase, such as deep brain stimulation or a dopamine pump
  • People who are unable to follow the study procedures
  • People who have abnormalities in their spine that would prevent surgery
  • People who have a condition that requires frequent MRI scans
  • People who are currently pregnant or breastfeeding
  • Women of childbearing age who do not have an effective or acceptable form of contraception
  • People who intend to become pregnant during the study
  • People who are unable or unwilling to use the study device or related equipment, as determined by the study team
  • People who are already taking part in another interventional study that could affect the results of this trial
  • The investigators running the trial, along with their family members, employees, or other dependants

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Jocelyne Bloch, MD, CHUV

Phone: +41 21 69 30762

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Ecole Polytechnique Fédérale de Lausanne
Registry
ClinicalTrials.gov
Start date
3 July 2025
Est. completion
1 May 2031

Where this trial is recruiting

🇨🇭 Switzerland

Primary endpoints

Occurrence of (serious) adverse device effects of the ARC-IM Therapy from baseline up to the end of the study.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov